CompletedPhase 2ACTRN12611001150932

Dyslipidaemia, Oxidative Stress And Arterial Wall Function In Non-Insulin Dependent Diabetes

A Double-Blind Randomised Placebo-Controlled Trial Of The Effects Of Fenofibrate And Coenzyme Q10 On Arterial Function In Type 2 Diabetic Subjects With Dyslipidaemia


Sponsor

Professor Gerald F Watts

Enrollment

80 participants

Start Date

Feb 1, 1997

Study Type

Interventional

Conditions

Summary

To assess whether the combination of fenofibrate and coenzyme Q improves vascualr health in diabetes


Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 75 Yearss

Inclusion Criteria2

  • Type 2 diabetes
  • Dyslipidaemia (fasting serum triglycaeride >1.8mmol/L or HDL-cholesterol <1.0mmol/L, with total cholesterol <6.5mmol/L and total cholesterol-to-HDL-cholesterol ratio >4)

Exclusion Criteria4

  • Use of antioxidant or lipid-regulating therapy, insulin, angiotensin-converting enzyme inhibitors, calcium antagonists or aspirin
  • Body mass index >40kg/m2
  • Uncontrolled hypertension (>160/90mmHg)
  • Serum creatinine >150umol/L

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

1.Fenofibrate 200mg/day orally 2.Coenzyme Q10 200mg/day orally 3.Fenofibrate 200mg/day plus Coezyme Q10 200mg/day orally 4.Placebo All for 12 weeks

1.Fenofibrate 200mg/day orally 2.Coenzyme Q10 200mg/day orally 3.Fenofibrate 200mg/day plus Coezyme Q10 200mg/day orally 4.Placebo All for 12 weeks


Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12611001150932


Related Trials